Kirsten Drejer, M.Sc., Ph.D. Co-founder and CEO Dr. Drejer has more than 20 years of experience in the pharmaceutical industry. Before joining Symphogen, she held several scientific and managerial positions at Novo Nordisk A/S, including four years as Director of Diabetes Discovery, and three years as Corporate Facilitator. In addition to her service on Symphogen's board of directors, Dr. Drejer is also a member of the board of directors of Danisco A/S and Bioneer A/S. Her scientific experience includes research and development of drugs for the treatment of Diabetes and she was instrumental in the Insulin Analogue and Nasal Insulin programs of Novo Nordisk.
	John Haurum, M.D., D.Phil Co-founder and CSO Dr. Haurum received a D.Phil. in immunology from the Institute of Molecular Medicine, University of Oxford. Subsequently, he took up a position as Assistant Professor at the Danish Cancer Society and completed his medical training. He has extensive research experience in molecular immunology and biochemistry and has published more than 35 articles. He has served as a consultant for several Danish biotech companies, and holds a Scandinavian International Management Institute (SIMI) diploma in Managing Medical Product Innovation.
	Thomas Feldthus, M.Sc., MBA Co-founder and CFO Before joining Symphogen, Mr. Feldthus served as Investment Manager at Novo A/S. Between 1996 and 1999 he was Corporate Development Manager at Novo Nordisk A/S, and prior to that he was Director of Business Development at Cheminova Agro A/S. Mr. Feldthus has extensive experience with business development, international sales, marketing, and project management and holds a M.Sc. from the Technical University of Denmark and an MBA (Sloan Fellow) from London Business School.
	Søren Bregenholt, Ph.D. Senior Vice President, Project and Portfolio Management Søren Bregenholt joined Symphogen from a position as Investment and Project Manager at Novo Nordisk A/S. He received his Ph.D. in immunology from University of Copenhagen and worked as a post doctoral fellow at the Pasteur Institute in Paris, France. He has solid Project Managing experience from both drug discovery and development projects. Since joining Symphogen in 2002, he has held various managing positions. He has published more than 45 papers in international scientific journals.
	Christian Meyer, M.D., Ph.D.  Vice President, Clinical Research, Medical and Regulatory Affairs  Christian Meyer has more than 10 years of clinical research and drug development experience from academia, pharma and biotech. He has served in several scientific, project management and managerial positions within Clinical Drug Development at Novo Nordisk A/S and Zymenex A/S, with responsibility for both early and late stage biopharmaceutical drug development projects within a wide range of indications. He is a fully licensed practitioner and received his Ph.D. in Clinical Science from the University of Copenhagen. He holds authorship on more than 15 scientific publications.